MESO
Price
$10.51
Change
+$0.06 (+0.57%)
Updated
Jun 25, 12:53 PM (EDT)
Capitalization
1.29B
63 days until earnings call
SAGE
Price
$9.19
Change
-$0.03 (-0.33%)
Updated
Jun 25, 01:18 PM (EDT)
Capitalization
577.38M
41 days until earnings call
Interact to see
Advertisement

MESO vs SAGE

Header iconMESO vs SAGE Comparison
Open Charts MESO vs SAGEBanner chart's image
Mesoblast
Price$10.51
Change+$0.06 (+0.57%)
Volume$100
Capitalization1.29B
Sage Therapeutics
Price$9.19
Change-$0.03 (-0.33%)
Volume$2.94K
Capitalization577.38M
MESO vs SAGE Comparison Chart in %
Loading...
MESO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MESO vs. SAGE commentary
Jun 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MESO is a Buy and SAGE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 25, 2025
Stock price -- (MESO: $10.45 vs. SAGE: $9.22)
Brand notoriety: MESO and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MESO: 72% vs. SAGE: 79%
Market capitalization -- MESO: $1.29B vs. SAGE: $577.38M
MESO [@Biotechnology] is valued at $1.29B. SAGE’s [@Biotechnology] market capitalization is $577.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.36B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MESO’s FA Score shows that 0 FA rating(s) are green whileSAGE’s FA Score has 0 green FA rating(s).

  • MESO’s FA Score: 0 green, 5 red.
  • SAGE’s FA Score: 0 green, 5 red.
According to our system of comparison, SAGE is a better buy in the long-term than MESO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MESO’s TA Score shows that 5 TA indicator(s) are bullish while SAGE’s TA Score has 5 bullish TA indicator(s).

  • MESO’s TA Score: 5 bullish, 6 bearish.
  • SAGE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SAGE is a better buy in the short-term than MESO.

Price Growth

MESO (@Biotechnology) experienced а -11.21% price change this week, while SAGE (@Biotechnology) price change was +1.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.26%. For the same industry, the average monthly price growth was +35.95%, and the average quarterly price growth was +19.76%.

Reported Earning Dates

MESO is expected to report earnings on Aug 27, 2025.

SAGE is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+4.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MESO($1.29B) has a higher market cap than SAGE($577M). SAGE YTD gains are higher at: 69.797 vs. MESO (-47.222). MESO has higher annual earnings (EBITDA): -77.78M vs. SAGE (-358.98M). SAGE has more cash in the bank: 424M vs. MESO (37.7M). SAGE has less debt than MESO: SAGE (11.9M) vs MESO (126M). SAGE has higher revenues than MESO: SAGE (47.4M) vs MESO (5.67M).
MESOSAGEMESO / SAGE
Capitalization1.29B577M223%
EBITDA-77.78M-358.98M22%
Gain YTD-47.22269.797-68%
P/E RatioN/AN/A-
Revenue5.67M47.4M12%
Total Cash37.7M424M9%
Total Debt126M11.9M1,059%
FUNDAMENTALS RATINGS
MESO vs SAGE: Fundamental Ratings
MESO
SAGE
OUTLOOK RATING
1..100
531
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
6338
P/E GROWTH RATING
1..100
9797
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAGE's Valuation (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for MESO (88) in the Biotechnology industry. This means that SAGE’s stock grew somewhat faster than MESO’s over the last 12 months.

SAGE's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MESO (100) in the Biotechnology industry. This means that SAGE’s stock grew similarly to MESO’s over the last 12 months.

MESO's SMR Rating (95) in the Biotechnology industry is in the same range as SAGE (98) in the Pharmaceuticals Other industry. This means that MESO’s stock grew similarly to SAGE’s over the last 12 months.

SAGE's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as MESO (63) in the Biotechnology industry. This means that SAGE’s stock grew similarly to MESO’s over the last 12 months.

SAGE's P/E Growth Rating (97) in the Pharmaceuticals Other industry is in the same range as MESO (97) in the Biotechnology industry. This means that SAGE’s stock grew similarly to MESO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MESOSAGE
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
72%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
78%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 16 days ago
81%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 14 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
MESO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARTGX25.630.41
+1.63%
Artisan Global Value Investor
JRASX85.381.35
+1.61%
Janus Henderson Research S
BUFIX23.38N/A
N/A
Buffalo International
HSUTX65.59N/A
N/A
Rational Dynamic Brands Instl
BRSBX13.14N/A
N/A
MFS Blended Research Small Cap Eq B

MESO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MESO has been closely correlated with SAGE. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if MESO jumps, then SAGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MESO
1D Price
Change %
MESO100%
+2.85%
SAGE - MESO
66%
Closely correlated
-0.86%
QTTB - MESO
51%
Loosely correlated
+3.92%
ZURA - MESO
33%
Poorly correlated
+8.04%
TNGX - MESO
33%
Poorly correlated
+0.75%
AVTX - MESO
32%
Poorly correlated
+3.34%
More

SAGE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAGE has been loosely correlated with AXON. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SAGE jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAGE
1D Price
Change %
SAGE100%
-0.86%
AXON - SAGE
42%
Loosely correlated
+1.41%
CBIO - SAGE
41%
Loosely correlated
-1.54%
PHIO - SAGE
40%
Loosely correlated
+1.38%
HRMY - SAGE
38%
Loosely correlated
+0.41%
KZR - SAGE
36%
Loosely correlated
+3.99%
More